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Abstract 
 
With older and ageing populations, patients experience multiple chronic diseases at the 
same time. Individual chronic disease guidelines often recommend pharmacological 
therapies as a key intervention, resulting in patients being prescribed multiple regular 
medications for their different diseases. Whilst the term ‘polypharmacy’ has been applied to 
the use of multiple medications, there is no consistent definition and this term is now being 
used all inclusively. To improve both scientific rigor and optimal patient care, it is crucial that 
a standard terminology is used which reclassifies the term ‘polypharmacy’ into distinct 
phenotypes relating to the index chronic disease, additional conditions to the index 
(‘comorbidity’) or the experience of multiple chronic conditions at the same time 
(multimorbidity). 
 
Using three exemplar index conditions; heart failure, type 2 diabetes and breast cancer, we 
propose the reclassification of the term ‘polypharmacy’ into three distinct phenotypes. First, 
index drug or multi-index drug therapy, where each index condition creates multiple drug use 
for that condition; second, co-drug therapy, where addition of other comorbid conditions 
increases the multiple drug use and may influence the management of the index disease and 
third, multi drug therapy, where adult population with multimorbidity may be on many    
drugs. 
 
This paper reviews guidelines for the individual exemplars to develop the basis for the new 
terms and then develops the pharmaco-epidemiology of multiple drug use further by 
reviewing the evidence on the relationship between the phenotypic classification and 
important outcomes. The importance of standardising ‘polypharmacy’ terminology for the 
scientific agenda and clinical practice is that it relates to an index condition or disease safety 
outcomes including drug interactions, adverse side effects in hospital admissions and related 
‘polypill’ concept. 
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What is new? 
 
The paper proposes alternative terminology for polypharmacy which links the use of multiple 
drugs to comorbidity and multimorbidity using three exemplars. 
 
What this adds to what is known? 
The term polypharmacy is applied to a variety of clinical scenarios and in particular to the 
use of multiple drugs in the same person. However it does not meet the scope nor scientific 
rigor needed for clinical practice or research. 
 
What is the implication? 
 
The benefits of the proposed more sensitive definition relate to scientific rigor to compare 
evidence using a more structured and standard definition and measure efficacy of outcomes 
following drug intervention models and better understanding of case mix when classifying 
diseases and drug treatments in populations. 
 
What should change now? 
 
The three distinct phenotypes proposed are (i) index drug or multi-index drug therapy, 
where each index condition creates multiple drug use for that condition; (ii) co-drug therapy, 
where addition of other comorbid conditions increases the multiple drug use and may 
influence the management of the index disease and (iii) multi drug therapy, where adult 
population with multimorbidity may be on many drugs. 
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Background 
 
 
Drugs play a key role in the routine management of chronic diseases including preventing 
progression and improving prognosis, management of physiological symptoms (e.g. pain) 
and improving mental health problems.1 Some of the many different examples include the 
endocrine system (e.g. diabetes)2, cardiovascular system (e.g. heart failure)3 and now 
increasingly cancer4 which, with improving prognosis, is also managed as a chronic long- 
term condition. The current evidence-based approach to clinical management has meant 
that multiple drug prescribing has been translated into routine clinical practice via national 
and local guidelines.5,6,7 
 
Individual chronic disease guidelines often include recommendations on different 
medications and the implementation of each guideline results in a patient with at least two or 
more drug classes, often initiated at the onset for treatment, control or the prevention of 
linked diseases. Yet, the individual patient experience is often of two or more chronic 
conditions at the same time, which is an issue not just for the old, but for the larger 
population experiencing chronic diseases. Therefore, people experiencing multiple diseases 
will have an escalating number of drugs for each individual condition. This phenomenon has 
been increasingly cited in literature8,9 and many studies have been incorporating the use of 
multiple drugs by patients under the umbrella term ‘polypharmacy’.10,11 However, there are 
problems with this approach as the term ‘polypharmacy’ has varied meanings, which include 
the number of drugs, any medications associated with ageing or the adverse events for 
multiple drug combinations.12 For example, in a systematic review, over 80% of studies had 
used different numerical values to define polypharmacy and the remainder had used 
alternative definitions relating to the care context or other descriptive statements.13 The term 
‘polypharmacy’ in practice and research has come to be an inclusive generic term for any 
type of terminology, which reduces the ability to observe more complex relationships 
between specific drug combinations and outcomes14 or to compare studies which have used 
different criteria and definitions. The other key scientific gap is the lack of any clear 
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definitions which link the specific combination of multiple chronic diseases to the prescribing 
or use of multiple drugs. This link is crucial as the status of the chronic disease and the use 
of drugs as an intervention, are implicitly linked to evidence for future clinical and healthcare 
outcomes. 
 
In scientific literature, people who experience multiple chronic diseases have been defined 
into the distinct but related concepts of comorbidity or multimorbidity. Comorbidity is defined 
as the study of a primary index disease in the context of the other diseases, or as the 
consequence, but multimorbidity is defined as the experience of two or more chronic 
diseases by an individual.15 Despite clear epidemiological and increasingly clinical 
approaches to the experience of multiple conditions, no such definitions have been applied 
to multiple drug use in an individual, nor how multiple drugs might link to the disease status. 
There is a clear necessity that the experience of multiple chronic conditions and the 
associated scale of drug use in the larger population require standard definitions. The term 
‘polypharmacy’ fails to meet the scope of this topic and this umbrella term needs to 
distinguish between disease indications for drug treatment and ‘polypharmacy’ in older 
populations. 
 
In the following sections, three empirical examples of type 2 diabetes, heart failure and 
breast cancer are used to delineate the concepts by using the current evidence-based 
guidelines and the implications of multiple drug use for each condition are drawn out. A case 
with all three conditions is then used to illustrate the links between disease, multiple 
diseases and multiple drug use, concluding with a proposal for standard definitions and 
epidemiological approaches to multiple drug use in adult populations (Table 1). 
 
 
Chronic disease guidelines and drug recommendations 
 
 
1. Type 2 diabetes mellitus 
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Clinical context – In patients with established type 2 diabetes mellitus, patients will often start 
with a Biguanide (e.g. Metformin) but alternative will include Sulphonylurea (e.g. 
Gliclazide).2,5 If the patient remains poorly controlled, then there may either be the addition of 
insulin or other oral anti-diabetic drugs. In terms of prevention approaches, other adjunct 
drugs that may be rapidly initiated are aimed at the reduction of cardiovascular outcomes, 
and renal or ocular complications. In patients with type 2 diabetes, at the age of 45 years, it is 
estimated that around 40% have hypertension and by the age of 75 years around 60% have 
hypertension or comorbid cardiovascular and renal complications.16,17 So the potential   
range of other drug classes that could be used in patients with type 2 diabetes include anti- 
hypertensives, the specific use of ACE (Angiotensin Converting Enzyme) inhibitors or statins 
for lipid lowering. 
 
Epidemiological definitions – The index disease status in this example is type 2 diabetes 
mellitus type 2. The other comorbid diseases in this population may include complications 
such as hypertension and cardiovascular disease which require drug treatment or other 
conditions that may influence the index condition, for example, depression.18 
 
Pharmaco-epidemiology definitions – The drugs that are initiated are usually dependent on 
the severity of presentation, but the index drug therapy for type 2 diabetes mellitus is most 
often a Biguanide (i.e. Metformin). The requirement for optimal diabetic control may require 
the addition of other anti-diabetic drugs, such as other oral hypoglycaemics or insulin i.e. 
multi-index therapies. The co-drug therapy in diabetic population may include anti- 
hypertensives (i.e. ACE inhibitors), lipid lowering drugs, and specific drugs indicated for 
other chronic diseases that impact on the type 2 diabetes. However, there may also be co- 
drug therapy that potentially negatively impacts the index disease under this definition too 
e.g. steroids in diabetes.19 
 
 
 
2. Heart failure with left ventricular systolic dysfunction (LVSD) 
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Clinical context – There are a range of CVD drugs used in HF with LVSD, with some that are 
recommended in all patients and others that are indicated and used depending on the 
clinical severity and comorbidity. Common comorbidity in HF populations includes 
hypertension (73%), chronic obstructive pulmonary disease (31%) and chronic kidney 
disease (46%).20 Using the American and European national guidance for HF6,21, there are 
five CVD drug groups that might be prescribed for HF. Current evidence recommends that 
both ACEi and Beta-receptor blockers are prescribed as first line treatment for all patients 
with LVSD who do not have other clinical contra-indications. The other four drug groups 
depending on the clinical context and severity include: (i) aldosterone antagonists, (ii) 
angiotensin-2 receptor antagonists, (iii) vasodilators such as hydralazine and nitrates and 
(iv) digoxin. In addition, diuretics are used in all patients as required depending on clinical 
indication. 
 
Epidemiological definitions – The index disease status in this example is heart failure with 
LVSD. The other comorbid diseases in this population may include conditions such as atrial 
fibrillation and ischaemic heart disease which require specific drug treatments or other 
conditions that may influence the index condition. 
 
Pharmaco-epidemiology definitions – The drugs that are initiated are usually dependent on 
the severity of presentation, but the index drug therapies for heart failure with LVSD are 
usually an Angiotensin Converting Inhibitor (e.g. Ramipril) and cardio-selective beta-receptor 
blocker (e.g. Bisoprolol). The requirement for effective symptom control may require the 
addition of other drugs, such as angiotensin-2 receptor antagonists (ARBs) or diuretics i.e. 
multi-index drug therapies. The co-drug therapy in heart failure with LVSD population 
may include anti-hypertensives (e.g. Amlodipine), statins and anti-coagulants, and specific 
drugs indicated for other chronic conditions that influence the heart failure status adversely 
e.g. anti-depressants.22 
 
 
 
3. The example of breast cancer 
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Context – There is increasing interest in how the comorbidity status for cancer patients 
influences outcomes. Examples of common comorbidity in the breast cancer population 
aged 75 years and over include cardiovascular disease (55%), hypertension (32%), diabetes 
(32%), COPD (10%), and dementia (7%).23,24 Whilst such evidence is beginning to accrue, 
the current approaches to treatment are mainly dependent on the type and stage of breast 
cancer. Yet, there is an absolute necessity for standard definitions as multiple drug 
treatments in breast cancer change and on-going treatment creates issues of comorbid 
disease complications and surveillance safety. 
 
This example provides the ultimate challenge to the pharmaco-epidemiology phenotype 
definition as treatment options are wide-ranging and change over time for the acute and 
chronic phases. Drugs used in breast cancer now include specific targets (e.g. receptor 
status determined by genetic risk) with some patients having multiple lines of sequential 
chemotherapies that may be as a short course or prolonged until there is disease 
progression.25,26 Current drug classes cover: (i) combination chemotherapy, (ii) hormone 
therapy or (iii) targeted biological therapy, each with their own sub-classes. The drug 
treatment covers initial therapy and the long-term therapy usually through use of hormone 
drug regimens, as the effectiveness of treatment has led to becoming a chronic ‘disease’ 
state with increased or normal survival times. 
 
At initiation of treatment, the one chemotherapy agent considered as an option in absence of 
contraindication, in all breast cancer patients is an anthracycline, often in the form of 
Epirubicin (in NICE UK guideline).27 Other initiating therapies can be tailored to the stage and 
include E-CMF – epirubicin, cyclophosphamide, methotrexate and fluorouracil) or FEC 
(fluorouracil, epirubicin, cyclophosphamide). Another drug class that most patients will have 
in their chemotherapy is taxanes such as docetaxel or paclitaxel.28 When and how they are 
given will depend on the individual patient, e.g. nodal involvement will have docetaxel as part 
of their adjuvant treatment; paclitaxel tends to be given in metastatic disease; whereas triple 
receptor negative patients may have carboplatin before any taxane is used. 
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Some patients may have multiple lines of sequential chemotherapy, such as a short course 
of taxanes or prolonged treatment until disease progression or toxicities emerge. For 
metastatic disease, additional interventions include monoclonal agents such as trastuzumab 
or emtansine.29 Often when deciding on the next line of therapy, pre-existing toxicities from 
previous lines of chemotherapies, as well as their co-morbidities and drug history are 
accounted for in the decision-making process. 
 
The breast cancer example illustrates the direct issues between the concepts of comorbidity 
and multiple drug therapy. Pre-cancer comorbidity influences treatment options as well as 
the cancer drug treatment subsequently influencing the emergence of other complicating 
comorbidities. For example, anthracyclines, trastuzumab and taxanes are responsible for 
some of the acute and long term cardiotoxicities, in particular heart failure, and other 
complications such as liver and renal disease.30 Other toxicities include bevacizumab which 
influences hypertension and capecitabine which is being investigated in triple negative 
cancers31, as an alternative or in addition to standard chemotherapy which influences 
angina.32 
In terms of potential co-drug therapies, these include hormonal treatments such as 
tamoxifen or anastrozole.33 These breast cancer treatments on their own create conflict 
issues with other co-drug therapies such as antidepressants, warfarin or allopurinol.34,35 
 
 
Epidemiological definitions – The index status in this example is breast cancer. The other 
comorbid diseases in this population may include conditions related to drug treatments such 
as heart, liver or renal disease or conditions which affect the index cancer. 
 
Pharmaco-epidemiology definitions – The drugs that are initiated are usually dependent on 
the stage of breast cancer, and usually there are multi-index drug therapies which are 
combination of up to several chemotherapies (e.g. epirubicin, cyclophosphamide, 
methotrexate and fluorouracil or cyclophosphamide, epirubicin and fluorouracil). The 
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co-drug therapy in breast cancer population may include symptomatic control (for example, 
anti-emetics, corticosteroids, iron), as well as specific drugs for other chronic diseases that 
influence the onset or progression of the cancer or are a consequence of the cancer.36 
However, here there is an additional distinct concept for defining the use of multiple drugs, 
which is the distinction between the acute phase treatment and the longer-term chronic 
treatment in the breast cancer remission state. In the breast cancer example, index multi- 
drug therapies will be used, but in the longer-term treatment an index follow-up therapy, 
such as Tamoxifen will be used.37 The cancer example is in contrast to the other diabetes 
and heart failure example, where drugs once added usually result in a lifelong use and are 
rarely stopped only because of side effects. In breast cancer ‘chronic disease’ scenario there 
are distinct and different phases of drug treatment, which balance between the acute pro- 
active drug treatments compared to the potential longer-term preventative treatment. 
 
4. A multimorbid patient with type 2 diabetes, LVSD heart failure and breast cancer 
 
 
If a patient were to have all three conditions at the same time, the utility of the terminology is 
further strengthened (Figure 1). The index multi-drug and co-drug would combine together 
to create a separate phenotype which is multi-drug therapy. The multi-drug therapy 
definition would then apply to the combination of any index and co-drug therapies and any 
additional drugs prescribed for specified diseases or conditions. The term does not need to 
be referenced necessarily to any index condition so that the focus is on the patient taking all 
their drugs. In the above sections the focus was on conditions related to index or 
comorbidity, especially when influences the treatment and outcomes of an index condition. 
However as the patient and populations age, other drugs will be added for other conditions, 
which means that multi-drug therapy is the summation of all potential treatments. 
A further point is the way in which multi-drug therapy occurs. For chronic conditions like 
diabetes and heart failure there may be gradual increase in number of drugs but in cancer, 
the prescribing cascade may be rapidly turn into multi-drug-therapy. For conditions such as 
cancer and heart failure, and additional feature may be the initiation of the frailty state38 
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which may further increase drug treatments, and the combination of disease and frailty is 
further associated with adverse outcomes. 
 
 
 
Setting pharmaco-epidemiology phenotypes within current evidence on outcomes 
 
 
The following sections will illustrate how the epidemiological definitions, as applied to the 
three exemplar conditions, are associated with outcomes. This alignment of phenotypes to 
outcomes under-pins the rationale for the proposed pharmaco-epidemiology phenotypes and 
the importance of a more sensitive definition to describe the prescription of multiple drugs 
used by patients. Using the proposed definitions, index therapy outcomes relate to 
improving the prognosis of the index disease; co-drug therapy outcomes relate to 
improvement or worsening of the index disease as well as interactions between the index 
drug and co-drug therapies. Finally, multi-drug therapy outcomes focus on patient centred 
outcomes and health prioritisation. 
 
Index drug therapy outcomes 
 
 
For type 2 diabetes, the key initiating drug is often Metformin39,40 and evidence has shown 
that it is associated with improved diabetes outcomes and cardiovascular outcomes.41 Whilst 
there are other oral hypoglycaemics (sulphonylurea or SGLT2 inhibitors) that may be added 
to improve control, Metformin is still the main indicative drug for T2D. There is evidence that 
adding sulphonylyurea42 or insulin43 improves diabetes control but not necessarily the 
outcomes over long-term. Evidence on the long-term benefits of other drug classes, such as 
glitazones44 and new SGLT2 inhibitors,45,46 is just emerging and Metformin still remains the 
first line treatment in current clinical practice. 
 
For heart failure with LVSD, the key initiating drug treatment is with multi-index drug 
therapies of Angiotensin Converting Enzyme (ACEi) and beta-receptor blockers.47 
Angiotensin-converting–enzyme (ACE) inhibition reduces overall mortality by 16 to 40%, 
reduces hospitalisations for asymptomatic HF patients with reduced ejection fraction48 and 
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improves quality of life.49 The use of beta-blocker therapy, once considered counterintuitive, 
is now a standard guideline recommendation, with evidence of a mortality benefit.50 
 
The evidence on breast cancer combination drug approaches is complex, with no single 
drug or combinations being the preferred approach, which is dependent on the type of 
tumour, extent of metastases and whether it is receptor sensitive.51,52 The same 
chemotherapies are also used for other types of cancers, so here the value of terminology 
relates to logging the primary treatment in medication history with diagnosis. 
 
 
 
Co-drug therapy outcomes 
 
 
The purpose of the co-drug therapy definition is that it provides the standard terminology for 
common drug treatments that impact on the management or prognosis of an index disease. 
So, for T2D, common co-drug therapies such as anti-hypertensives and statins are important 
in the prevention of the clinical sequelae of T2D.53,54 In addition to the beneficial and possible 
synergistic effects of index and co-drug therapies for improving disease outcomes, other co- 
drug therapies may have antagonistic or harmful effects on the index condition or its 
management. Examples in T2D are the hyperglycaemic effects of corticosteroids55 or the 
severe and prolonged hypoglycemic effects of some lipid lowering agents e.g gemfibrozil, 
which interfere with the metabolism of some short-acting secretagogues e.g. repaglimide.56 
Conversely over-treatment of the index type 2 diabetes mellitus may also lead to adverse 
outcomes as in the case of heart failure and mortality outcomes.57 
 
For HF with LVSD, common co-therapy drugs that might have a beneficial effect on HF 
outcomes include anticoagulants such as warfarin58 or anti-arrhythmics such as Amiodarone, 
both prescribed for AF comorbidity.59 However, other co-drug therapies regularly prescribed 
for other concomitant conditions can have an antagonistic effect on index drug therapies. 
Clear examples include the sodium and fluid retention and increased systemic vascular 
resistance associated with nonsteroidal anti-inflammatory drugs (e.g. Diclofenac, Ibuprofen) 
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and the pro-arrhythmic effects of antidepressants such as amitriptyline.60,61 Heart failure is 
also commonly associated with frailty, and this may also affect the cardiovascular 
outcomes.62 
 
For breast cancer, other co-drug therapies could include symptomatic control of pain or 
nausea63,64, as well as treatment of any complications. However, cancer patients are 
particularly susceptible to drug interactions particularly in the presence of malnutrition and 
renal or hepatic dysfunction. A common example of adverse co-therapy is in the increased 
risk of bleeding from Warfarin in the presence of anti-neoplastic agents.65 
 
All three chronic conditions have a higher risk of co-morbid depression which influences self- 
care management of the index condition and means that anti-depressants often feature as a 
long-term co-drug therapy.66 
 
 
 
Multi-drug therapy outcomes 
 
 
The above sections show how a patient experiencing just these 3 conditions will quickly 
arrive at a multi-drug state. The implicit drivers for this phenotype is the single disease 
guidelines which promote the use of the individual index drugs or co-drug combinations to 
improve outcomes but also potentially influence adverse outcomes. In ageing populations 
the number of diseases and associated multi-drug therapies increase with a reported 20% of 
adults older than 65 years prescribed 10 or more medications.67 Whilst each individual set of 
multi-index and co-drug therapies have specific benefits, the culmination of such multi-drug 
therapies is associated with adverse outcomes including quality of life, disability, hospital 
admissions and mortality.68-70 Whilst any drugs without clear indication should be removed, 
prioritisation of remaining disease indicated drug therapies should take account of patient 
preferences for health goals.71 
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Discussion 
 
Using the three case examples of chronic illness which includes the novel implications of 
cancer, our paper proposes and provides the definitions for multiple drug use in patients with 
multiple chronic illnesses and diseases. It links the use of multiple drug use to the specific 
terms of comorbidity and multimorbidity, and provides the distinct scope of terminology which 
is currently not specifically embraced by the term ‘polypharmacy’. The terms it proposes    
are index drug therapy or multi-index therapies (and index follow-on therapy as in              
the specific case of cancer), co-drug therapies, multi-drug therapies and total drug therapy. 
The importance of clear and standard terminology relates to the chronic disease model72 in 
which the goal is on improvement of the clinical outcomes or patient-reported outcomes. 
Whilst, drug treatments are one key component of the multi-faceted interventions which 
include non-drug therapies, the sole aim and purpose of multiple drug use is to maximise the 
patient and population benefit and gain the best outcomes. 
By proposing clear definitions and terminology and application to the index disease status, 
comorbidity or multimorbidity, a consistent approach to the clinical and research 
management can be developed. The benefits of the terminology will be helping clinicians to 
review potentially harmful multiple drugs by being able to structure them using an organising 
principle e.g. a HF specialist might start with the adverse co-therapy drugs whereas a 
gerontologist for a frail patient might start on any drugs that don’t influence patient important 
outcomes. The downfall of a vague definition such as ‘polypharmacy’ and benefits of the 
proposed more sensitive definition are potentially in terms of (i) de-prescribing - clinicians  
can perform drug reviews using an organising principle.73 This might be looking first at any 
non-indicated drug therapies followed by harmful co-therapy drugs when managing the index 
disease, or at patient priorities when managing older frail patients with multi-drug therapy 
when drug-drug interactions are common,74 (ii) scientific rigor – the ability to compare 
evidence using a more structured and standard definition and measure efficacy of outcomes 
following drug intervention models and (iii) public health – better understanding of case mix 
when classifying diseases and drug treatments in populations. Overall the key strength of 
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the new classification is that it enables alignment of conditions with drug interventions, 
outcomes and patient priorities. 
 
These definitions also potentially underpin the key scientific concept of the ‘polypill’75 and the 
drug typology of interactions, safety and side effects. Conceptualising the ‘polypill’ as index 
drug therapies or co-drug therapies provides the framework by which dimensions of disease 
and drugs could be included. Whilst the ‘polypill’ concept uses multiple drug combinations as 
a potential benefit to patients and populations, the converse problem is that the 
multimorbidity creates drug-drug interactions and inappropriate prescribing in older 
populations.76   Review of current guidelines shows that drug-drug interactions are common 
and associated with hospitalisation, which further supports the characterisation of the multi- 
drug phenotype to identify the level and grade of such interactions.77-79 Other studies have 
also shown the potential effect on quality of life and patient safety in older populations.80-83 A 
recent study on patient safety has suggested there are over 200 medication errors per year 
in the UK and adverse drug reactions associated with these could account for several 
thousand deaths per year.84 The term ‘polypharmacy’ implicitly covers the implications for the 
patient and population in which drug interventions are a key part of disease prevention      
and chronic disease management model. It may be assumed by society and by clinical 
guidelines that polypharmacy is a good thing but really, we don’t know that to be the case 
and won’t do until there’s good evidence of how multiple drug use for specific indications is 
linked with patient outcomes. 
 
The paper illustrates through the index case examples, how multiple drug use originates 
when each disease treatment model is applied and how that use translates into use of 
multiple drugs in an individual patient who has, for example, type 2 diabetes, heart failure 
and cancer together at the same time. This creates an imperative that standard terminology 
is employed when trying to understand this field for clinical and research purposes. 
Arguably, there may be a view that different terminology may be over-elaborating the term 
‘polypharmacy’. Conversely, the alternative and clear view proposed in the paper is that it is 
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vitally important to understand the underlying origins of multiple drug use which links single 
disease drug treatment to multiple disease drug treatment and how that relates to clinical, 
healthcare, safety or patient outcomes. 
 
In conclusion, using three different chronic disease examples, our paper proposes the 
replacement of the term ‘polypharmacy’. By linking an index condition with the associated 
multi-index drug use, to the associated comorbidity conditions with related co-drug use to all 
other non-related disease indicated drugs, provides the basis of clearer understanding of the 
older person with multimorbidity who has overall ‘polypharmacy’. The importance of 
providing a clear phenotype classification for ‘polypharmacy’ enables the key link to the 
potential mechanisms, such as drug interaction and safety that ultimately relates to the 
improvement of clinical and healthcare outcomes in chronic disease management. 
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Table 1: Linking disease status to drug phenotypes 
 
 
Disease definitions Disease status Drug phenotypes Indicator drugs 
Index disease 
 
 
 
Comorbidity 
 
 
 
 
Multimorbidity 
diabetes mellitus type 2 
 
 
 
hypertension, 
cardiovascular disease 
 
 
 
diabetes mellitus, 
hypertension, chronic 
kidney disease, plus 
other chronic conditions 
Index drug therapy 
Index multi-drug therapy 
 
 
Co-drug therapy 
 
 
 
 
Multi-drug therapy 
biguanide 
biguanide, sulphonylurea 
or insulin 
 
anti-hypertensives 
(specifically ACEi), lipid 
lowering drugs, other 
chronic diseases 
 
biguanide, sulphonylurea, 
insulin, anti- 
hypertensives, lipid 
lowering drugs 
Index disease 
 
 
 
 
 
 
Comorbidity 
 
 
 
 
Multimorbidity 
heart failure with LVSD 
 
 
 
 
 
 
atrial fibrillation, 
ischaemic heart disease 
 
 
 
heart failure, 
hypertension, chronic 
kidney disease 
Index drug therapy 
Index multi-drug therapy 
 
 
 
Co-drug therapy 
 
 
 
 
Multi-drug therapy 
ACEi and Beta-blocker 
 
ARB, Aldosterone 
Antagonists, Digoxin, 
Hydralazine/Nitrate 
Diuretics 
 
nitrates, anti-coagulants, 
aspirin, statins, 
amlodipine, amioderone, 
digoxin 
 
ACEi, beta-blockers, 
diuretics, nitrates, digoxin 
and other drugs 
Index disease 
 
 
 
 
Comorbidity 
Multimorbidity 
 
 
Index chronic disease 
breast cancer 
 
 
 
 
organ involvement 
 
 
breast cancer, 
cardiovascular, renal or 
bone disease 
complications 
 
breast cancer in 
remission 
Index drug therapy 
 
Index disease multi-drug 
therapies 
 
Co-drug therapies 
Multi-drug therapies 
 
 
Index follow-up therapy 
chemotherapy 
 
combination 
chemotherapy 
 
anti-emetics, 
corticosteroids, iron 
 
cancer, symptom, chronic 
disease, anti-depressants 
 
 
 
tamoxifen 
*An additional term not linked to any condition but all the drugs that a patient uses is total drug therapy 
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